Shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) hit a new 52-week high during trading on Wednesday . The stock traded as high as $4.17 and last traded at $4.14, with a volume of 2970700 shares traded. The stock had previously closed at $3.89.
Wall Street Analyst Weigh In
Several analysts have recently commented on ABCL shares. Leerink Partners started coverage on shares of AbCellera Biologics in a research report on Monday. They set an "outperform" rating and a $5.00 price objective for the company. KeyCorp increased their price target on AbCellera Biologics from $4.00 to $5.00 and gave the stock an "overweight" rating in a report on Wednesday, April 16th. Leerink Partnrs raised AbCellera Biologics to a "strong-buy" rating in a research note on Monday. Finally, Truist Financial lowered their price objective on AbCellera Biologics from $28.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, May 16th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $7.50.
View Our Latest Research Report on ABCL
AbCellera Biologics Stock Up 1.1%
The company has a 50-day moving average price of $2.75 and a two-hundred day moving average price of $2.75. The stock has a market capitalization of $1.27 billion, a P/E ratio of -7.58 and a beta of 0.62.
AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.02. The company had revenue of $4.24 million during the quarter, compared to analyst estimates of $7.12 million. AbCellera Biologics had a negative return on equity of 15.98% and a negative net margin of 737.56%. On average, sell-side analysts expect that AbCellera Biologics Inc. will post -0.59 earnings per share for the current year.
Institutional Trading of AbCellera Biologics
A number of institutional investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of AbCellera Biologics by 248.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 15,671,063 shares of the company's stock valued at $34,946,000 after purchasing an additional 11,171,063 shares during the period. EntryPoint Capital LLC boosted its stake in shares of AbCellera Biologics by 11.3% during the first quarter. EntryPoint Capital LLC now owns 187,822 shares of the company's stock valued at $419,000 after purchasing an additional 19,140 shares during the period. Virtu Financial LLC purchased a new stake in shares of AbCellera Biologics during the first quarter valued at approximately $52,000. Invesco Ltd. boosted its stake in shares of AbCellera Biologics by 114.6% during the first quarter. Invesco Ltd. now owns 24,146 shares of the company's stock valued at $54,000 after purchasing an additional 12,893 shares during the period. Finally, Federated Hermes Inc. boosted its stake in shares of AbCellera Biologics by 3.4% during the first quarter. Federated Hermes Inc. now owns 947,751 shares of the company's stock valued at $2,113,000 after purchasing an additional 31,514 shares during the period. Hedge funds and other institutional investors own 61.42% of the company's stock.
AbCellera Biologics Company Profile
(
Get Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
See Also
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.